AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01951716
Drug: Graded Glucose Infusion with Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Starting at 0 minutes, glucose infusion rates will be increased to 1, 2, 3, 4, 6, and 8 mg/kg/min every 40 minutes.~Starting at 0 minutes, a primed-continuous intravenous infusion of saline containing 1% human albumin will continue for 240 minutes.~The study is finished at 240 minutes.
Trial: NCT01951716
Drug: Graded Glucose Infusion with GIP Alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Starting at 0 minutes, glucose infusion rates will be increased to 1, 2, 3, 4, 6, and 8 mg/kg/min every 40 minutes.~Starting at 0 minutes, a primed-continuous intravenous infusion of GIP in saline containing 1% human albumin will continue for 240 minutes.~The study is finished at 240 minutes.
Trial: NCT01951716
Drug: Graded Glucose Infusion with xenin-25 alone
RxNorm normalized name: glucose 25 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Starting at 0 minutes, glucose infusion rates will be increased to 1, 2, 3, 4, 6, and 8 mg/kg/min every 40 minutes.~Starting at 0 minutes, a primed-continuous intravenous infusion of xenin-25 in saline containing 1% human albumin will continue for 240 minutes.~The study is finished at 240 minutes.
Trial: NCT02389400
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Single Group Assignment
Trial: NCT01133951
Drug: OAC triple therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole, 20mg, amoxicillin, 1000mg, and clarithromycin, 500mg, all twice a day for 2 weeks.
Trial: NCT01133951
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole placebo, amoxicillin placebo, and clarithromycin placebo, all twice a day for 2 weeks.
Trial: NCT02675868
Drug: Norepinephrine
RxNorm normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Noradrenaline is an endogenous catecholamine with sympathomimetic effects. It has mainly α-adrenergic receptor selectivity but also β-effects in higher concentrations. It will be administered at 0.05 μg/kg/min, a clinical relevant dose on the low end of the scale.
Trial: NCT02675868
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NaCl 0.9% infusion
Trial: NCT01951716
Drug: Graded Glucose Infusion with GIP plus xenin-25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Starting at 0 minutes, glucose infusion rates will be increased to 1, 2, 3, 4, 6, and 8 mg/kg/min every 40 minutes.~Starting at 0 minutes, a primed-continuous intravenous infusion of GIP plus xenin-25 in saline containing 1% human albumin will continue for 240 minutes.~The study is finished at 240 minutes.
Trial: NCT01951716
Drug: Meal Tolerance Test with Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: At 0 minutes, a liquid mixed meal (Boost Plus) plus acetaminophen will be ingested.~Starting at 0 minutes, a primed-continuous intravenous infusion of saline containing 1% human albumin will continue for 300 minutes.~The study is finished at 300 minutes.
Trial: NCT05269810
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 tablets b.i.d for 8 weeks
Trial: NCT02839642
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00632762
Drug: mantadix
RxNorm normalized name: chlorcyclizine hydrochloride / hydrocortisone acetate Topical Cream [Mantadil]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dose greater or equal to 200 mg/day and progressively increasing doses (100mg every 3 days until the pre-study dose is reached).
Trial: NCT01951716
Drug: Meal Tolerance Test with xenin-25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: At 0 minutes, a liquid mixed meal (Boost Plus) plus acetaminophen will be ingested.~Starting at 0 minutes, a primed-continuous intravenous infusion of xenin-25 in saline containing 1% human albumin will continue for 300 minutes.~The study is finished at 300 minutes.
Trial: NCT03738241
Drug: AS03
RxNorm normalized name: AS03 Adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AS03 oil-in-water emulsion-based adjuvant system containing DL-alpha-tocopherol, squalene, polysorbate 80, and a buffer.
Trial: NCT01440374
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg matching placebo daily (50 mg for subjects of East Asian heritage), intra-subject dose escalations to a maximum dose of 300 mg matching placebo (150 mg for subjects of East Asian heritage)
Trial: NCT02788656
Drug: Angiotensin-Converting Enzyme Inhibitor
RxNorm normalized name: Angiotensin-converting enzyme inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional, guideline-directed therapy for heart failure and reduced ejection fraction
Trial: NCT01537653
Drug: SAR231893 (REGN668)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:Solution in a vial Route of administration: Subcutaneous injection
Trial: NCT01537653
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:Solution in a vial Route of administration: Subcutaneous injection
Trial: NCT05108051
Drug: ZSP1273
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZSP1273 tablets 600mg administered orally once daily
Trial: NCT02607813
Drug: PDR001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biological: PDR001 anti-PD1 antibody
Trial: NCT02261415
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g saline bolus injection + 1 g saline infusion from induction over 8 hours
Trial: NCT04261920
Drug: Huangqi Guizhi Wuwu decoction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The experimental group took Huangqi Guizhi Wuwu decoction twice a day, infused with warm water. Consistently used during patients receiving XELOX5 adjuvant chemotherapy for at least 12 weeks (every 3 week is a cycle, 4 cycles).~The control group took placebo twice a day, infused with warm water. Consistently used during patients receiving XELOX5 adjuvant chemotherapy for at least 12 weeks (every 3 week is a cycle, 4 cycles).
Trial: NCT03454243
Drug: RXDX-106
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive continuous daily oral doses of RXDX-106 in 21 day cycles. To determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D), study drug will be administered in an escalated fashion starting at dose of 10 mg/day and will proceed at the dose levels prespecified by the dose escalation schema. Once daily dosing for RXDX-106 will initially be tested. However, other dosing schedules (eg, every other day, weight based, etc) may be tested based on safety and PK data to optimize drug exposure.
Trial: NCT03667326
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral capsule, PO
Trial: NCT01011426
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 capsule po 6 hours after surgery; repeat in 12 hours if no flatus
Trial: NCT02539537
Drug: 5-Fluoro-uracil
RxNorm normalized name: Fluoro Uracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01123655
Drug: APLA12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention: Drug treatment will be stopped or interrupted if indicated. Medical care will be provided at no cost to the patient.
Trial: NCT01123655
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug treatment will be stopped or interrupted if indicated. Medical care will be provided at no cost to the patient.
Trial: NCT03817268
Drug: Capecitabine monotherapy
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine is administered within 6 weeks after resection and after adequate recovery. To reduce the side effects and improve patient compliance, the administered dose is half of the recommendation: 625 mg/m2, bis in die (BID) (1250 mg/m2 per day). A 2-week therapy is followed by a 1-week pause, and a cycle includes 3 weeks. A total of 8 cycles is planned for each patient.
Trial: NCT04675021
Drug: AZD6094 (Savolitinib) film coated tablets 600 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD6094 (Savolitinib) ilm Coated Tablet 200 mg x 3
Trial: NCT04675021
Drug: [14C]-AZD6094 (Savolitinib) Solution for Infusion, 20 μg/mL (NMT 37.0 kBq/5 mL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14C AZD6094 (Savolitinib) Solution for Infusion (20 μg/mL (NMT 37.0 kBq/5 mL)
Trial: NCT04675021
Drug: [14C] AZD6094 (Savolitinib) Oral Solution, 300 mg (NMT 4.1 MBq)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14CAZD6094 (Savolitinib) Oral Solution (300 mg NMT 4.1MBq)
Trial: NCT00567710
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules
Trial: NCT01719653
Drug: SUPREP
RxNorm normalized name: Suprep Bowel Prep Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SUPREP consumed as described in each arm.
Trial: NCT00733993
Drug: Caffeine 150 MG
RxNorm normalized name: caffeine 150 MG
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Across five separate testing days, subjects were administered two placebo doses, 20 mg amphetamine, 150 mg caffeine, and 300 mg caffeine in counterbalanced fashion
Trial: NCT03609047
Drug: Docetaxel / cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant Chemotherapy
Trial: NCT03609047
Drug: doxorubicin/cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant Chemotherapy
Trial: NCT03609047
Drug: epirubicin/cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant Chemotherapy
Trial: NCT03239210
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo equivalent
Trial: NCT00733993
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Across five separate testing days, subjects were administered two placebo doses, 20 mg amphetamine, 150 mg caffeine, and 300 mg caffeine in counterbalanced fashion
Trial: NCT00733993
Drug: Caffeine 300 MG
RxNorm normalized name: caffeine 300 MG
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Across five separate testing days, subjects were administered two placebo doses, 20 mg damphetamine,150 mg caffeine, and 300 mg caffeine in counterbalanced fashion
Trial: NCT00107120
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo once daily for up to 8 weeks
Trial: NCT00718354
Drug: Standard Chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigator's discretion
Trial: NCT00892021
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00121056
Drug: Enbrel®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00121056
Drug: Kineret®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03506477
Drug: Enstilar® foam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: for 4 weeks
Trial: NCT02243657
Drug: ASP3652
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT02243657
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT03966066
Drug: erythromycin
RxNorm normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3-5mg/kg.d orally for 6 months
Trial: NCT00876928
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: medium chain triglyceride given once per week
Trial: NCT03339128
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablets
Trial: NCT02908347
Drug: MP1032
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hard gelatine capsules containing 50 mg MP1032 as active ingredient
Trial: NCT02908347
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hard gelatine capsules without active ingredient
Trial: NCT00167310
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g of Placebo (soy bean oil) in 4 x 500 mg capsules daily for baseline, 1 month, 2 months and 4 months
Trial: NCT03306836
Drug: Heparin Sodium
RxNorm normalized name: Heparin Sodium
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Infused with 5000 IU of Heparin Sodium
Trial: NCT03306836
Drug: Heparin Sodium
RxNorm normalized name: Heparin Sodium
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Infusion Heparin Sodium at a rate of 18 IU / kg.h
Trial: NCT06004947
Drug: CCX168
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT00350181
Drug: CY
RxNorm normalized name: CYT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For subjects aged 18-60 with lymphoma 100 mg/kg, IV For subjects aged with AML, ALL or CML 18-50 60 mg/kg, IV For subjects aged 51-60 with MDS, AML or ALL or patients age 18-60 with MDS, secondary AML or non-CML myeloproliferative disease 45 mg/kg
Trial: NCT06004947
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT03802591
Drug: CS1001 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participant will receive CS1001 placebo antibody by intravenous infusion every 3 weeks(Q3W), for up to 24 months
Trial: NCT03802591
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered by oral, twice a day on Day 1 - Day 14 of each cycle.
Trial: NCT02708459
Drug: Bupevecaine
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02708459
Drug: Dexmedetomedine
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01037244
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets via oral administration before an attempt at sexual intercourse.
Trial: NCT04541186
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo
Trial: NCT00710164
Drug: XSCR capsule (Composed of Traditional Chinese Medicine Huangqi, Chuanxiong, Chishao, Danggui, Dilong, Taoren, Honghua.)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14 days of XSCR capsule
Trial: NCT00710164
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14 days of Placebo
Trial: NCT04333927
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capecitabine (1,330 mg/m2 per day, in divided doses twice daily, 7 days per week).
Trial: NCT00537862
Drug: Enteric-Coated Mycophenolate Sodium (EC-MPS)
RxNorm normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01224795
Drug: Placebo Comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Peramivir, administered intravenously.
Trial: NCT00464607
Drug: hMG-IBSA
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01502631
Drug: SUN13837 injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SUN13837 injection, injection 1 x daily for 28 doses
Trial: NCT04539977
Drug: TQB2450
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inductive therapy: TQB2450 + EC(4 cycles) Maintenance therapy: TQB2450+EC(2 cycles) followed byTQB2450 (1 year)
Trial: NCT01502631
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo, volume equivalent to injection 1 x daily for 28 doses
Trial: NCT01036802
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02025608
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00000498
Drug: antihypertensive agents
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00582790
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid will be given on day 1 intravenously over 15 or 30 minutes starting at 400mcg. If no significant increase in gamma delta-T cell augmentation is seen, the dose of zoledronic acid will be increased in the subsequent cycle up to a maximum dose of 3mg.
Trial: NCT02447367
Drug: JLP-1207(Fed)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fed followed by fasted in period 1, the subjects will receive an oral pill of JLP-1207 under fed condition
Trial: NCT03904355
Drug: Gonadotropins
RxNorm normalized name: GONADOTROPINS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gonadotropin stimulation of follicular growth
Trial: NCT03043196
Drug: SRP plus Rosuvastatin gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SRP followed by Rosuvastatin placement into intrabony defect
Trial: NCT03043196
Drug: SRP plus placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SRP followed by placebo gel placement into intrabony defect
Trial: NCT02102555
Drug: IV acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of one gram of IV acetaminophen given in pre-operative area
Trial: NCT02102555
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo (IV normal saline)
Trial: NCT02500927
Drug: ASP8273 Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT02500927
Drug: ASP8273 Capsules A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT03229889
Drug: Flomax 0.4Mg Capsule
RxNorm normalized name: Flomax 0.4mg Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamsulosin is an alpha-blocker that has been shown to relax smooth muscle in the genitourinary system. Patients will be asked to 1 pill for 7 days prior to surgery.
Trial: NCT03229889
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is plant cell based pill that contains no active ingredient. Patients will be asked to 1 pill for 7 days prior to surgery.
Trial: NCT00354458
Drug: Comparator: Placebo (unspecified)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rolofylline Pbo 30 mg IV QD; 3 days
Trial: NCT00840320
Drug: 1278863
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15mg, 25mg, 50mg, 150mg
Trial: NCT00840320
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo
Trial: NCT02201563
Drug: Minocycline
RxNorm normalized name: Minocycline
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral minocycline (100mg twice a day) for 3 months
Trial: NCT00324532
Drug: ProBactrix
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01237678
Drug: IMGN901
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase 2 regimen is IMGN901, Carboplatin, and Etoposide. IMGN901 to be given on days 1 and 8 every 21 days.
Trial: NCT00482950
Drug: PHX1149T
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03754413
Drug: comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No-treatment
Trial: NCT03043053
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo nasal spray
Trial: NCT00264212
Drug: irbesartan and irbesartan-hydrochlorothiazide
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01627665
Drug: D->R->C+R
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one oral dose DABIGATRAN 300 mg -\> RIVAROXABAN 40 mg -\> 1g/day CLARITHOMYCINE with RIVAROXABAN 40 mg
Trial: NCT01627665
Drug: D->R->C+D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one oral dose DABIGATRAN 300 mg -\> RIVAROXABAN 40 mg -\> 1g/day CLARITHOMYCINE with one oral dose DABIGATRAN 300 mg
Trial: NCT01627665
Drug: R->D->C+D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RIVAROXABAN 40 mg -\> one oral dose DABIGATRAN 300 mg -\> 1g/day CLARITHOMYCINE with one oral dose DABIGATRAN 300 mg
Trial: NCT01627665
Drug: R->D->C+R
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RIVAROXABAN 40 mg -\> one oral dose DABIGATRAN 300 mg -\> 1g/day CLARITHOMYCINE with RIVAROXABAN 40 mg
Trial: NCT00469131
Drug: tacrolimus + mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02139540
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50% nitrogen \[inert\]/50% oxygen - otherwise completely identical administration and setup
Trial: NCT02845674
Drug: OTX-101 0.09%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.09% cyclosporine nanomicellar solution
Trial: NCT00176449
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparable placebo
Trial: NCT02966834
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2330672 matching placebo will be supplied as white film-coated tablets.
Trial: NCT02966834
Drug: GSK2330672
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2330672 will be supplied in 2 dose strengths of 10 mg and 45 mg white film-coated tablets.
Trial: NCT02656160
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 3 hrs before sleep
Trial: NCT01931384
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline intramuscularly on the day of embryo transfer and 5 days after embryo transfer.
Trial: NCT00296517
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects with Major Depressive Disorder who were randomised to placebo to match Bupropion SR during the treatment period.
Trial: NCT00333528
Drug: Human butyrylcholinesterase (HuBChE) derived from human plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular administration
Trial: NCT00333528
Drug: Placebo: Normal saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular administration